We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Consensus vs. actual, and revenue trend
Rating & price-target changes
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Stored first · Google News · Yahoo Finance (English)
Gene and Cell Therapies Targeting CNS Disorders Market Expected to Experience Accelerated Growth and Market Evolution by 2036 – DelveInsight | Brainstorm Cell Therapeutics, MeiraGTx, Voyager Thera - Barchart.com
Gene and Cell Therapies Targeting CNS Disorders Market Expected to Experience Accelerated Growth and Market Evolution by 2036 – DelveInsight | Brainstorm Cell Therapeutics, MeiraGTx, Voyager Thera Barchart.com
The Escalator: VML Health, BrainStorm Cell Therapeutics, Syneos Health and more - Medical Marketing and Media
The Escalator: VML Health, BrainStorm Cell Therapeutics, Syneos Health and more Medical Marketing and Media
Brainstorm Cell (BCLI) director discloses 150,000-share stock option grant - Stock Titan
Brainstorm Cell (BCLI) director discloses 150,000-share stock option grant Stock Titan
[EFFECT] BRAINSTORM CELL THERAPEUTICS INC. SEC Filing - Stock Titan
[EFFECT] BRAINSTORM CELL THERAPEUTICS INC. SEC Filing Stock Titan
BrainStorm Cell Therapeutics Proposes FDA Regulatory Reforms for ALS and Regenerative Medicine Clinical Trials - geneonline.com
BrainStorm Cell Therapeutics Proposes FDA Regulatory Reforms for ALS and Regenerative Medicine Clinical Trials geneonline.com
BrainStorm Cell Therapeutics Announces Publication Calling for Updated FDA Approaches to ALS, Rare Diseases and Regenerative Medicine - Yahoo Finance
BrainStorm Cell Therapeutics Announces Publication Calling for Updated FDA Approaches to ALS, Rare Diseases and Regenerative Medicine Yahoo Finance
| Quarter | Date | Time | EPS est. | EPS actual | Surprise | Rev. est. | Rev. actual | Status |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 05. 14. | After market close (AMC) | $-0.29 | — | — | $0 | — | Scheduled |
| Date | Firm | Analyst | Action | Rating change | Price target | Report |
|---|---|---|---|---|---|---|
| 2024. 07. 11. | Maxim Group | — | Upgrade | Hold → Buy | — | Maxim Group: Hold → Buy |
| 2023. 09. 28. | Maxim Group | — | Downgrade | Buy → Hold | — | Maxim Group: Buy → Hold |
| 2023. 03. 31. | Maxim Group | — | Maintain | — → Buy | — | Maxim Group: Buy |
| 2021. 02. 05. | Maxim Group | — | Upgrade | Hold → Buy | — | Maxim Group: Hold → Buy |
| 2018. 05. 15. | HC Wainwright & Co. | — | Initiate coverage | — → Buy | — | HC Wainwright & Co.: Buy |
| 2017. 08. 18. | Maxim Group | — | Maintain | — → Buy | — | Maxim Group: Buy |
As of FY2026Q1 · Source: SEC/DART + price data
No holdings data to show.